Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Cell and Bioscience(2)
Biomedicine and Pharmacotherapy(1)
Current Neuropharmacology(1)
Expert Opinion on Drug Discovery(1)
Journal of Alzheimer's Disease(1)
Área temáticas
Enfermedades(6)
Farmacología y terapéutica(6)
Fisiología humana(5)
Medicina y salud(3)
Ingeniería química(1)
Origen
scopus(7)
A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
ArticleAbstract: Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the globaPalabras claves:Alzheimer’s disease, BACE1, BDNF, cognitive decline, dendritic spines, high-fat diet, neuroinflammation, Rhein-huprine hybrid, Tau, TLR4Autores:Antoni Camins, Auladell C., Bulló M., Cano A., Espinosa-Jimenez T., Ettcheto M., Folch J., Muñoz-Torrero D., Olloquequi J., Parcerisas A., Pont C., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
ReviewAbstract: Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-Palabras claves:ADAM10, Alzheimer's disease, Natural compounds, Pharmaceutical, α-SecretaseAutores:Antoni Camins, Busquets O., Cano A., Cominetti M.R., Di Luca M., Endres K., Ettcheto M., Manzine P.R., Marcello E., Olloquequi J., Pelucchi S.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusExperimental models for aging and their potential for novel drug discovery
ReviewAbstract: Background: An interesting area of scientific research is the development of potential antiaging druPalabras claves:aging, Heterogeneous mice model, IGF-1, mTOR, Resveratrol, SAMP8, SirtuinsAutores:Antoni Camins, Auladell C., Busquets O., Casadesús G., Ettcheto M., Folch J., Miguel Marin, Olloquequi J., Pallás M., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusPharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease
ReviewAbstract: To deeply understand late onset Alzheimer's disease (LOAD), it may be necessary to change the concepPalabras claves:BDNF, dendritic spines, late onset Alzheimer's disease, neuroinflammation, obesity, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Casadesús G., Castro-Torres R.D., Espinosa-Jimenez T., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Sureda F.X., Verdaguer E.Fuentes:scopusThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
ArticleAbstract: Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor thPalabras claves:dyskinesia, entacapone, Opicapone, Parkinson’s Disease, tolcaponeAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus